Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) PT at $14.44

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average recommendation of “Buy” by the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $12.75.

A number of equities analysts recently weighed in on the stock. Scotiabank assumed coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, March 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $1.71 on Friday. Perspective Therapeutics has a 52 week low of $1.62 and a 52 week high of $19.05. The company’s 50 day moving average price is $2.65 and its two-hundred day moving average price is $5.67.

Insiders Place Their Bets

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 22,026 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The shares were bought at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the stock in a transaction on Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, with a total value of $81,630.30. Following the transaction, the director now directly owns 108,982 shares in the company, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 115,696 shares of company stock valued at $256,344. 3.52% of the stock is currently owned by corporate insiders.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at about $33,000. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics in the 4th quarter valued at approximately $34,000. National Bank of Canada FI lifted its stake in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares during the period. ProShare Advisors LLC boosted its position in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after purchasing an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in Perspective Therapeutics in the fourth quarter worth $51,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.